WP03 Evaluation

Share this post


O3.1 to assure and evaluate that the CAN.HEAL project is implemented as planned and

it accomplishes the objectives defined.

O3.2 to assure that the produced knowledge and outcomes meet high-quality standards,

are appropriately disseminated and communicated, and have a relevant impact on the

‘Genomics for Public Health’ and ‘Cancer diagnosis and treatment for all’ EU-wide, as a

way to ensure the sustainability of the project and its outcomes after its execution.

O3.3 to provide guidelines and tools for the evaluation to ensure equity,

accessibility, and scalability of value-based innovation adoption in personalized medicine

to improve access to individuals and cancer patients to prevention, diagnosis, and

treatment programs.

WP3 will develop an Evaluation Plan (the quality of outputs and outcomes; involvement of different stakeholders; achievement objectives) by creating a tool (questionnaires, checklist, and working groups) for systematic and continuous monitoring of processes, outputs, outcomes, and context.

Equity mainstreaming will include mapping existing guidelines and tools, as well as, best practices for mainstreaming equity in cancer prevention and control programmes and policies. A specific guide and related tools will be internally developed and promoted to support and monitor the entire project in addressing equity and gender-sensitive approach.

WP3 will develop a dynamic and multidimensional impact assessment –( tool (incl. foresight scenarios & sustainable implementation scenarios), as follows: Map existing initiatives, expertise, and requirements for reimbursement and implementation of NGS tools. Construct an infrastructure to enable actual data input, according to the “living” reviews performed for COVID-19. Develop and promote a DMIA tool, (examples of tools that could be included for performing HTAs, (cost –) effectiveness, budget impact, value-based healthcare). The tool will be pilot tested in cooperation with the Organisation of European Cancer Institutes, working group health economics, by using 10% of the budget for this specific task.

WP3 will also develop an innovation adoption and integration assessment framework for the

evaluation of the NGS programmes including Initial mapping of existing unmet need assessment, business case definition, value-based procurement, and demand-driven innovation assessment frameworks. Co-creation of guidelines and recommendations

for the evaluation of the NGS programmes and use cases therein to: 1) support and monitor the project in addressing a sustainable impact of the demand-driven innovation and scalable adoption of the innovation and 2) ensure a good integration into the health systems at country and EU level.